Dapagliflozin and empagliflozin were efficient in reducing the main outcome in patients older than 65 years, patients with diabetes mellitus, patients with ischemic HFrEF and patients treated with angiotensin receptor/neprilysin inhibitor. Here, MME is linked to diabetes mellitus.